Trametinib is an FDA‐approved, allosteric inhibitor of MEK1/2 used to treat NRAS‐mutant melanoma, both as a monotherapy and in combination with other anti‐cancer drugs (Johnson & Puzanov, 2015). This evidence concerns the gene MAP2K1 and melanoma.